Market Risers: AstraZeneca, Compass Group, easyJet

Broker Ratings

The stock price for AstraZeneca with ticker code: LON:AZN has moved up 2.25% or 195 points during today’s session so far. Market buyers have remained optimistic throughout the session. The periods high figure was 8982 and hitting a low of 8825.94. The amount of shares exchanged has so far reached 1,224,569 with the daily average traded share volume around 2,273,368. A 52 week high for the stock is 8982 around 314 points different to the previous business close and a 52 week low sitting at 6736 which is a difference of 1932 points. AstraZeneca now has a 20 simple moving average of 8486.06 and now the 50 day SMA of 8471.68. The market capitalisation is now £137,609.38m at the time of this report. The stock is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for AstraZeneca being recorded at Friday, September 24, 2021 at 12:04:20 PM GMT with the stock price trading at 8863 GBX.

Shares of Compass Group ticker lookup code: LON:CPG has stepped up 1.5% or 22 points throughout today’s trading session so far. Investors seem confident during the session. Range high for the period so far is 1493.5 and hitting a low of 1455. The number of shares traded by this point in time totalled 298,478 with the average number of shares traded daily being 3,095,047. The 52 week high for the share price is 1657.03 some 188.53 points difference from the previous days close and putting the 52 week low at 1029 is a variance of 439.5 points. Compass Group now has a 20 SMA at 1492.3 and also a 50 day moving average of 1501.23. Market capitalisation for the company is £26,591.00m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for Compass Group being recorded at Friday, September 24, 2021 at 11:52:31 AM GMT with the stock price trading at 1490.5 GBX.

Shares of easyJet EPIC code: LON:EZJ has increased 4.42% or 28.89 points in today’s trading session so far. Investors are a positive bunch throughout the session. Range high for the period has seen 683.41 meanwhile the session low reached 644.6. Volume total for shares traded at this point reached 1,641,146 with the average number of shares traded daily being 7,413,234. The stock 52 week high is 921.89 which is 268.09 points difference from the previous close and the 52 week low at 385.43 making a difference of 268.37 points. easyJet now has a 20 moving average of 662.48 and now the 50 day moving average now of 691.05. The current market cap is £5,172.24m at the time of this report. Share price is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for easyJet being recorded at Friday, September 24, 2021 at 11:52:27 AM GMT with the stock price trading at 682.69 GBX.

Share on:

Latest Company News

AstraZeneca’s Imfinzi plus BCG approved by FDA for high-risk bladder cancer

AstraZeneca’s Imfinzi has been approved in the US in combination with BCG for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer, based on Phase III POTOMAC trial results showing improved disease-free survival.

AstraZeneca’s Enhertu recommended for EU approval in HER2-positive solid tumours

AstraZeneca and Daiichi Sankyo’s Enhertu has received a positive CHMP opinion for adults with previously treated unresectable or metastatic HER2-positive solid tumours who have no satisfactory treatment options.

AstraZeneca and Daiichi Sankyo secure FDA approval for Enhertu in early breast cancer

The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu for both neoadjuvant and adjuvant treatment of HER2-positive early breast cancer, based on results from the Phase III DESTINY-Breast11 and DESTINY-Breast05 trials.

Compass Group reports double-digit profit growth in HY 2026

Compass Group posted 9% revenue growth and 12% underlying operating profit growth in the six months to 31 March 2026, citing strong demand for outsourcing services and continued margin progression.

FDA approves AstraZeneca’s Saphnelo Pen for self-administration in SLE

AstraZeneca’s Saphnelo has received US approval as a once-weekly autoinjector for adults with systemic lupus erythematosus, offering a self-administered alternative to IV infusion.

Third positive Phase III trial supports AstraZeneca’s tozorakimab in COPD

High-level data from the MIRANDA study showed AstraZeneca’s IL-33-targeting biologic tozorakimab significantly lowered annualised moderate-to-severe COPD exacerbations and was generally well tolerated.

    Search